Zobrazeno 1 - 10
of 53
pro vyhledávání: '"John S. Lilleyman"'
Autor:
Jeanette Payne, Ajay Vora, Rachel Ward, Tim Eden, Sally E. Kinsey, Chris Mitchell, Sue Richards, John S. Lilleyman
In November1999, the UK childhood ALL trial, ALL 97, adopted CCG risk stratification and treatment regimens in favour of the UKALL approach due to concerns over lower event-free survival (EFS) in the UK compared to the US. A key new feature in the am
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b333f4e83c067ed7f129131dd272128a
https://ora.ox.ac.uk/objects/uuid:2d19ecbc-d202-4a49-a9f1-2fa4c6cdb6de
https://ora.ox.ac.uk/objects/uuid:2d19ecbc-d202-4a49-a9f1-2fa4c6cdb6de
Autor:
Rachel L. Harris, G. Reza Jalali, Frank Hill, Susan M. Richards, I. Jill Durrant, Ajay Vora, Christine J. Harrison, Tim O B Eden, Anthony H. Goldstone, Hazel M. Robinson, Zoë J. Broadfield, Kerry E. Barber, Sally E. Kinsey, M Martineau, Brenda Gibson, Ian Hann, Ian M. Franklin, Kan L. Cheung, Chris Mitchell, Anthony V. Moorman, John S. Lilleyman
Publikováno v:
British Journal of Haematology. 125:552-559
This study of children and adults with acute lymphoblastic leukaemia (ALL) is the largest series of patients with hypodiploidy (
Autor:
John S. Lilleyman
Publikováno v:
British Journal of Haematology. 123:586-589
Publikováno v:
Cancer Chemotherapy and Pharmacology. 50:33-36
Purpose. The aim of this study was to compare leucocyte and erythrocyte thioguanine nucleotide (TGN) cytotoxic metabolite concentrations in children with lymphoblastic leukaemia taking mercaptopurine (MP) or thioguanine (TG) as part of their long-ter
Autor:
John S. Lilleyman
Publikováno v:
British Journal of Haematology. 115:782-785
Autor:
Osborn B. Eden, Sally E. Kinsey, Ian Hann, Jm M. Chessells, Frank Hill, C. C. Bailey, Susan M. Richards, Darren Hargrave, John S. Lilleyman, Chris Mitchell
Publikováno v:
British Journal of Haematology. 112:293-299
In the last 20 years, the survival rate for children with acute lymphoblastic leukaemia (ALL) has markedly improved, largely owing to a decrease in relapses. However, children still die from complications of treatment and these are potentially preven
Autor:
John S. Lilleyman
Publikováno v:
Pediatric Drugs. 1:197-209
It is 50 years since the first effective drug for childhood lymphoblastic leukaemia (ALL) was described. At that time the outlook for such children was certain death. Now patients have an odds-on chance of normal health and life expectancy. Although
Autor:
John S. Lilleyman
Publikováno v:
British Journal of Haematology. 105:871-875
Publikováno v:
Medical and Pediatric Oncology. 29:252-255
Daily 6-mercaptopurine (6MP) forms the backbone of continuing chemotherapy for childhood lymphoblastic leukaemia (ALL). A major metabolic route is catalysed by thiopurine methyltransferase (TPMT). TPMT deficiency occurs in 1 in 300 individuals and re
Publikováno v:
Therapeutic Drug Monitoring. 19:382-385
Measurement of red cell 6-mercaptopurine (MP) derived 6-thioguanine nucleotide (TGN) and methylmercaptopurine metabolites (MeMPs) can be used to monitor therapy in children who are administered MP for childhood lymphoblastic leukemia. Red cell TGNs a